Voyager Therapeutics, Inc. (VYGR)
Nasdaq: VYGR · Biological Products, (No Diagnostic Substances) · Lexington, MA · filing with the SEC since 2015
Who owns Voyager Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
Millennium Management LLC holds 7.4% of Common Stock, par value $0.001 per share, as its SCHEDULE 13G/A filed Jul 31, 2026 says.
Directors and officers
16
report now, of 32 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Millennium Management LLC
SCHEDULE 13G/A · filed Jul 31, 2026 · Common Stock, par value $0.001 per share · 6.1% in Jan 26, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 24, 2025 · Common Stock
Armistice Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value · 5.87% in May 15, 2026
EcoR1 Capital, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · reported falling below 5%, from 6.8% in Feb 17, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What VYGR reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 9, 2026.
Insider tradesForm 4
11sales
0purchases
8sales on a scheduled plan
4people selling
$300,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 39 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO | 4 | $200,000 | 3 | 0 | $0 |
| Swartz Robin | President | 3 | $100,000 | 2 | 0 | $0 |
| Jorgensen Nathan D. | Chief Financial Officer | 1 | $0 | 1 | 0 | $0 |
| Carter Todd Alfred | Chief Scientific Officer | 3 | $0 | 2 | 0 | $0 |